<DOC>
	<DOC>NCT01501266</DOC>
	<brief_summary>The purpose of this study is to confirm the safety profile such as the frequency of serious adverse events or any unexpected adverse events and overall efficacy of Faslodex for long term treatment in daily clinical practice.</brief_summary>
	<brief_title>Faslodex Specific Clinical Experience Investigation</brief_title>
	<detailed_description>MC MD</detailed_description>
	<mesh_term>Fulvestrant</mesh_term>
	<criteria>Patients treated with Faslodex for the first time due to postmenopausal breast cancer</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>postmenopausal breast cancer</keyword>
	<keyword>Faslodex</keyword>
	<keyword>cohort</keyword>
</DOC>